Fosun Pharma’s Subsidiary’s Drug Application Accepted by National Medical Products Administration

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.

Shanghai Fosun Pharmaceutical announced that its subsidiary, Yaopharma Co., Ltd., has had its drug registration application for Bromhexine Hydrochloride Injection accepted by the National Medical Products Administration. This drug, intended for expectorant therapy in patients with difficulty in oral administration, marks a significant step in the company’s research and development efforts, with an investment of approximately RMB 1.64 million to date. The acceptance of this application could enhance Fosun Pharma’s market position and impact stakeholders positively by expanding its product offerings in the pharmaceutical industry.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a leading pharmaceutical company based in China, primarily engaged in the development, manufacturing, and distribution of pharmaceutical products. The company focuses on a wide range of healthcare products and services, including pharmaceuticals, medical devices, and diagnostic products, catering to both domestic and international markets.

YTD Price Performance: 14.20%

Average Trading Volume: 5,317

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $8.57B

See more data about 2196 stock on TipRanks’ Stock Analysis page.